Company news

Botanix Pharmaceuticals Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Botanix $70 Million Institutional Capital Raising

June 21, 2024

FDA Approves Sofdra

June 19, 2024

Final Sofdra Labelling Discussions with FDA

June 11, 2024

March 2024 Quarterly Activities Report and Appendix 4C

April 30, 2024

S&P DJI Announces March 2024 Quarterly Rebalance

March 1, 2024

Botanix Pharmaceuticals Half Year Report

February 27, 2024

December 2023 Quarterly Activities Report and Appendix 4C

January 30, 2024

NDA Resubmission Accepted and Approval Date Confirmed

January 21, 2024

Botanix Resubmission of NDA for Sofdra Completed

December 20, 2023

Successful Completion of Human Factors Study

December 13, 2023

FDA Confirms Approach to Sofdra NDA Resubmission

December 3, 2023

Successful Completion of $13.5m Institutional Placement

November 30, 2023

Botanix Placement Secures $13.5M to Fund Sofdra Launch Prep

November 26, 2023

Investor Presentation and Investor Meetings

October 30, 2023

September 2023 Quarterly Activities Report and Appendix 4C

October 30, 2023

Presentation- FDA Letter Requires Patient Instruction Update

September 25, 2023

FDA Letter Requires Patient Instruction Update

September 25, 2023

Response to ASX Price and Volume Query

September 20, 2023

Appendix 4E Preliminary Final Report

August 31, 2023

Appointment of Dr Howie McKibbon as CEO

August 24, 2023

June 2023 Quarterly Activities Report and Appendix 4C

July 30, 2023

Botanix Closes Capital Raising and Royalty Milestone Buyout

July 26, 2023

Botanix Capital Raising to Extinguish Milestone & Royalty

July 21, 2023

Botanix Pharmaceuticals: The West Australian | Botanix Pharmaceuticals secures $12.5m via an institutional placement

July 20, 2023

New Territory Licensed for Sofpironium Bromide with Kaken

June 5, 2023

March 2023 Quarterly Activities Report and Appendix 4C

April 28, 2023

Botanix successfully completes A$10m Placement

April 12, 2023

Botanix Raises A$10 million via Institutional Placement

April 5, 2023

FDA Mid-Cycle Review Meeting Successfully Completed

April 2, 2023

Half Yearly Report and Accounts

February 28, 2023

Press Article Correction

February 14, 2023

Appendix 4C - Quarterly

January 30, 2023

Confirmation Sofpironium Bromide NDA Formally Under Review

December 7, 2022

Placement Completion and Results of Share Purchase Plan

November 28, 2022

Share Purchase Plan Opens

November 8, 2022

A$5 million Institutional Placement and Share Purchase Plan

October 30, 2022

Botanix receives A$3.7m R&D Tax Incentive Refund

October 25, 2022

BOT Announces Promotion and Focus on NDA Approval Readiness

October 20, 2022

Positive BTX 1702 Phase 1b/2 Clinical Study for Rosacea

October 12, 2022

BOT Submits FDA New Drug Application for Sofpironium Bromide

September 25, 2022

Issue of First $7.0m Tranche of A$7.5m Placement Completed

September 12, 2022

Botanix Completes Successful A$7.5m Placement

September 1, 2022

Preliminary Final Report

August 30, 2022

Quarterly activities report and Appendix 4C

July 29, 2022

Change of Director's Interest Notice * 3

July 7, 2022

Application for quotation of securities - BOT

July 7, 2022

NDA Filing Accelerated and Trials Fully Enrolled

July 6, 2022

Dermatology Asset Acquired to Accelerate Path to Revenue

May 4, 2022

Appendix 4C - Quarterly

April 28, 2022

FDA Qualified Infectious Disease Product Status for BTX 1801

April 27, 2022

← Newer news releases · Older news releases →

Calls

Decks

The 5 newest of 62 decks. Every deck is listed under its year.